REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On July 28, 2026, the FDA released briefing documents regarding the Company’s lead trial for its drug vusolimogene oderparepvec, or RP1, for skin cancer. The briefing documents revealed the FDA has deemed the single-armed mid-stage study submitted by Replimune to support the drug’s approval as “non interpretable.” FDA reviewers stated the assessment used in the study “confounds interpretation of the reported efficacy results and limits FDA’s ability to verify the reported results.”

On this news, Replimune’s stock price fell $3.28, or approximately 38%, to close at $5.35 on July 28, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Replimune securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [e-mail], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.